Work

P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC

Year: 2018

Type: article

Study design: Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2018.08.901

Authors: J. Neal, R. Doebele, G. Riely, A. Spira, L. Horn, Z. Piotrowska, D. Costa, S. Zhang, D. Bottino, J. Zhu, D. Kerstein, S. Li, P. Jänne

Institutions: Stanford Medicine, Stanford Cancer Institute, Stanford University, University of Colorado Cancer Center, Memorial Sloan Kettering Cancer Center, Virginia Cancer Specialists, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Takeda Oncology (United States), Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2898375329

FWCI: 3.053

Cites:

Cited by: 28

Related to: 10